OOIR: Observatory of International Research

Papers

(The TQCC of Molecular Neurodegeneration is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
In Memoriam of John T. Trojanowski, MD, PhD 1946-2022	493
Mis-localization of endogenous TDP-43 leads to ALS-like early-stage metabolic dysfunction and progressive motor deficits	251
Retraction Note: Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5– implications for dementia with lewy bodies	251
LRRK2 kinase activity regulates Parkinson’s disease-relevant lipids at the lysosome	249
Mutations in PSEN1 predispose inflammation in an astrocyte model of familial Alzheimer’s disease through disrupted regulated intramembrane proteolysis	232
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application	215
Molecular hallmarks of excitatory and inhibitory neuronal resilience to Alzheimer’s disease	206
Regulation of the hippocampal translatome by Apoer2-ICD release	203
Tau interactome and RNA binding proteins in neurodegenerative diseases	178
Emerging targets of α-synuclein spreading in α-synucleinopathies: a review of mechanistic pathways and interventions	164
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	160
Cerebrospinal fluid markers link to synaptic plasticity responses and Alzheimer’s disease genetic pathways	146
Microglia sensing of peripheral signals that bridge the brain and body	130
Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration	120
A genome-wide search for pleiotropy in more than 100,000 harmonized longitudinal cognitive domain scores	118
Inhibition of soluble epoxide hydrolase confers neuroprotection and restores microglial homeostasis in a tauopathy mouse model	115
The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons	107
Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	104
Death-associated protein kinase 1-dependent SENP1 degradation increases tau SUMOylation and leads to cognitive dysfunction in a mouse model for tauopathy	101
Cautions on utilizing plasma GFAP level as a biomarker for reactive astrocytes in neurodegenerative diseases	100
Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer’s disease	100
Recombinant cathepsins B and L promote α-synuclein clearance and restore lysosomal function in human and murine models with α-synuclein pathology	96
Circadian clocks, cognition, and Alzheimer’s disease: synaptic mechanisms, signaling effectors, and chronotherapeutics	96
Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	92
Human VCP mutant ALS/FTD microglia display immune and lysosomal phenotypes independently of GPNMB	91

HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	88
Multi-region brain transcriptomic analysis of amyotrophic lateral sclerosis reveals widespread RNA alterations and substantial cerebellum involvement	87
Single-cell peripheral immunoprofiling of Lewy body and Parkinson’s disease in a multi-site cohort	85
The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap	85
Immunotherapy against tau fragment diminishes AD pathology, improving synaptic function and cognition	81
The role of NURR1 in metabolic abnormalities of Parkinson’s disease	81
Unravelling cell type-specific responses to Parkinson’s Disease at single cell resolution	80
In Memoriam of Edward H. Koo, MD 1954–2025	77
Correction: Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	75
Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease	74
Autophagic impairment in sleep–wake circuitry is linked to sleep loss at the early stages of Alzheimer’s disease	71
Combination therapy using GDNF and cell transplant in Parkinson’s disease	69
Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy	65
Repetitive transcranial magnetic stimulation alleviates motor impairment in Parkinson’s disease: association with peripheral inflammatory regulatory T-cells and SYT6	64
Entering the era of precision medicine to treat amyotrophic lateral sclerosis	64
α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease	63
Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis	63
APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants	63
BAX activation in mouse retinal ganglion cells occurs in two temporally and mechanistically distinct steps	63
Clinical progression and genetic pathways in body-first and brain-first Parkinson’s disease	61
A perspective on Alzheimer’s disease: exploring the potential of terminal/paradoxical lucidity and psychedelics	57
Correction: The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus	57
ASO-mediated knock-down of GPNMB in mutant-GRN and in Grn-deficient peripheral myeloid cells disrupts lysosomal function and immune responses	57
TMEM106B aggregation in neurodegenerative diseases: linking genetics to function	56
Deficits in mitochondrial TCA cycle and OXPHOS precede rod photoreceptor degeneration during chronic HIF activation	55
Using mass spectrometry to validate mouse models of tauopathy	54
Evidence suggesting that microglia make amyloid from neuronally expressed APP: a hypothesis	54
Common features of neurodegenerative disease: exploring the brain-eye connection and beyond (part 2): the 2021 pre-symposium of the 15th international conference on Alzheimer’s and Parkinson’s disease	53
Dementia with lewy bodies patients with high tau levels display unique proteome profiles	53
Methylome analysis of FTLD patients with TDP-43 pathology identifies epigenetic signatures specific to pathological subtypes	53
The PKCι-β-arrestin2 axis disrupts SORLA retrograde trafficking, driving its degradation and amyloid pathology in Alzheimer’s disease	53
Correction: HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	53
The transcription factor combination MEF2 and KLF7 promotes axonal sprouting in the injured spinal cord with functional improvement and regeneration-associated gene expression	50
RETRACTED ARTICLE: Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD	50
The endotoxin hypothesis of Alzheimer’s disease	49
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis	49
Contribution of amyloid deposition from oligodendrocytes in a mouse model of Alzheimer’s disease	49
Molecular mechanisms and consequences of TDP-43 phosphorylation in neurodegeneration	47
Neuropathology of incidental Lewy body & prodromal Parkinson’s disease	46
Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease	46
APOE genotype influences on the brain metabolome of aging mice – role for mitochondrial energetics in mechanisms of resilience in APOE2 genotype	45
The role of n-3-derived specialised pro-resolving mediators (SPMs) in microglial mitochondrial respiration and inflammation resolution in Alzheimer’s disease	45
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia	45
Diagnostic biomarkers for α-synucleinopathies- state of the art and future developments: a systematic review	45
Glial phagocytosis for synapse and toxic proteins in neurodegenerative diseases	44
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2	44
VCP suppresses proteopathic seeding in neurons	44
The Hippo signaling pathway as a therapeutic target in Alzheimer’s disease	43
Correction: Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease	43
Cerebrospinal fluid proteome profiling across the Alzheimer’s disease continuum: a step towards solving the equation for ‘X’	43

Mechanisms of astrocyte aging in reactivity and disease	43
Sex specific molecular networks and key drivers of Alzheimer’s disease	42
Correction: Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts	41
Interplay between astrocyte reactivity and APOE ε4 status is associated with accelerated pTau-related tau pathology in Alzheimer’s disease	40
Peripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis	40
Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	40
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP	39
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes	39
NF-κB is a critical mediator of post-mitotic senescence in oligodendrocytes and subsequent white matter loss	39
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer’s disease	39
GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice	39
Correction: Blood–brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	38
Correction: Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	38
Modulation of O-GlcNAc cycling influences α-synuclein amplification, degradation, and associated neuroinflammatory pathology	38
Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies	37
Current strategies in the management of dementia with lewy bodies and future directions based on disease pathophysiology	37
Proteomic analysis of APOEε4 carriers implicates lipid metabolism, complement and lymphocyte signaling in cognitive resilience	36
Nuclear pore and nucleocytoplasmic transport impairment in oxidative stress-induced neurodegeneration: relevance to molecular mechanisms in Pathogenesis of Parkinson’s and other related neurodegenerat	36
Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology	36
The role of inflammasomes in vascular cognitive impairment	35
Pathological characteristics of axons and alterations of proteomic and lipidomic profiles in midbrain dopaminergic neurodegeneration induced by WDR45-deficiency	35
Increased expression of mesencephalic astrocyte-derived neurotrophic factor (MANF) contributes to synapse loss in Alzheimer’s disease	35
Therapeutic potential of APP antisense oligonucleotides for Alzheimer’s disease and down syndrome-related Alzheimer’s disease	35
Proteomic landscape of Alzheimer’s disease: emerging technologies, advances and insights (2021 – 2025)	35
Correction: Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model	34
Resistant and Resilient mutations in protection against familial Alzheimer’s disease: learning from nature	34
Blood platelet factor 4: the elixir of brain rejuvenation	34
Targeted long-read sequencing to quantify methylation of the C9orf72 repeat expansion	34
Myelin dysfunction in aging and brain disorders: mechanisms and therapeutic opportunities	33
Synaptic dysfunction and glial activation markers throughout aging and early neurodegeneration: a longitudinal CSF biomarker-based study	33